Taiho Oncology Inc. Notice of Limited Distribution Network

This notice is for eligible 340B covered entities interested in purchasing a Taiho Oncology Inc. (Taiho) product, LONSURF® (trifluridine and tipiracil) tablets (NDCs 64842-1025, 64842-1020) for metastatic gastric or metastatic colorectal cancer, to provide information regarding the distribution model. Taiho operates a limited distribution network composed of five (5) specialty distributors and six (6) specialty pharmacies. This network was established to ensure the appropriate, consistent, and efficient delivery of LONSURF® to patients with metastatic gastric or metastatic colorectal cancer as well as to guarantee broad access to this medicine. This distribution network applies to all purchasers, whether 340B eligible or non-340B eligible entities, and it does not restrict the ability of eligible 340B entities to purchase LONSURF® at the 340B price.

For covered entities that dispense products to patients that are seeking to purchase one of Taiho's medicines for 340B outpatient use or for inpatient hospital use, please contact one of Taiho's network specialty distributor partners that service the 340B program:

Specialty Distributors

McKesson Plasma and Biologics
ASD Healthcare
Oncology Supply
Cardinal Specialty Health

Additionally, the list of our current limited distribution network partners is available on the Taiho corporate website here: https://www.taihooncology.com/us/authorized-distributors. This list is routinely updated as needed when product or network partner information changes.

Taiho is committed to compliance with its obligations under the 340B statute as well as the specialized needs of individuals with gastric and colorectal cancer. Our limited distribution network was designed to address this commitment without discriminating against 340B covered entity customers. If you have any questions about how to acquire LONSURF® for your patients, please contact your participating Taiho Oncology, Inc. Specialty Distributor.